Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 08, 2016 11:03 PM ET


Company Overview of QR Pharma, Inc.

Company Overview

QR Pharma, Inc. develops drugs for the treatment of mild cognitive impairment, Alzheimer's, Parkinson's, and Down Syndrome diseases. It offers Posiphen compound for mild cognitive impairment and early stage Alzheimer's disease; and Bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. QR Pharma, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.

1055 Westlakes Drive

Suite 300

Berwyn, PA 19312

United States

Founded in 2008





Key Executives for QR Pharma, Inc.

Founder, Chief Executive Officer, President and Director
Vice President of Operations
Vice President of Formulation
Strategic Advisor and Director
Compensation as of Fiscal Year 2015.

QR Pharma, Inc. Key Developments

QR Pharma Begins Collaboration on Posiphen and Huntington’s Disease

QR Pharma, Inc. announced a new collaborative research agreement with The Rockefeller University aimed at developing a treatment for Huntington's disease (HD). The collaboration will focus on preclinical research involving QRâ s lead drug candidate, Posiphen ®. Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine, if Posiphen lowers the levels of the toxic huntingtin protein in these cells, if it promotes differentiation into neuronal cells and, if it prolongs the cell life of the HD cells. Results from the collaboration could lead to clinical studies in HD patients.

QR Pharma, Inc. Appoints Management

QR Pharma, Inc. announced the election of Mr. Michael Hoffman as Chairman of the Board of Directors and Mr. Dhesh Govender as Director. Mr. M. B. Hoffman is a Partner of Riverstone Holdings LLC. Dhesh S.K. Govender is currently CEO and Founder of Tara Immuno-Oncology LLC.

Similar Private Companies By Industry

Company Name Region
Thompson Nutritionals, Inc. United States
Baylor Industries Inc United States
Rasiris Inc. United States
ToleroGenics, Inc. United States
Stealth BioTherapeutics Incorporated United States

Recent Private Companies Transactions

Private Placement
May 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact QR Pharma, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at